Has anybody considered that the drop was attributed to a short hedge fund covering? There was still a little less than 10% of the shares shorted on 9/13 which would have taken 16 days to cover at normal volume. If it were a long fund exiting they did a lousy job of selling their shares. If it were a short fund covering they did a nice job bring the pps down more than 10% before covering. At least this is what I hope occurred. It wouldn't hurt my feelings to see another short exit in the next couple of days as that might start the squeeze up.
They will take it down even further. Put your strong buy in at 4-4.25. GL
You would assume so or they would not be presenting. There are approximately 8000-10,000 Parkinson's surgeries per year worldwide and the surgery is used for other problems as well. Google "New technique for deep brain stimulation surgery proves accurate and safe" and you will see that surgeons are using real-time feedback from CT scanners. The big question is "How much better is ClearPoint than the CT scanner?"
Since I got in after the first raid, the PPS has dropped below $4 twice but not for long. This would be good news if true.
From last quarter CC:
Let me take a minute to talk about financial values. As you may have seen in our earnings release this afternoon, this is the first quarter in which we are providing guidance for investors. In the first half of 2013, we achieved growth in product revenue of 87% as measured by the product revenues for the same period in 2012. We expect to see a similar growth rate in our product revenues in the third quarter of 2013 compared with the third quarter of 2012.
In the fourth quarter of 2013, we expect an increase in that growth rate as measured against our product revenue in the fourth quarter of 2012. We expect this acceleration in our growth rate in Q4 as we believe our current investment in sales and marketing capabilities will begin to pay off. Based on these expected growth rates, we anticipate total product revenues for 2013 of $2.3 million to $2.7 million, which would equate to total revenues for 2013 of $3.2 million to $3.6 million.
Now, I want to point out that these are product revenues projected by the Company for 2013 do not include significant revenues from drug delivery procedures, as the drug therapies being delivered with ClearPoint are in clinical trials and have not received regulatory approval.
amen to that BUT if the lying, stinking, vermin shorts would leave I think the cheerleaders would put down there pom-poms.
All due respect I doubt there will be a settlement. The best biotech hedge funds have not bought in to AVNR to lose 70% in a couple of weeks.
This board is an echo chamber for longs and at the same time infested with shorts.
Risk is they lose the court case, the PPS drops by 75% it's game over.
Reward is PPS rises 50% on a court victory (these are my guesstimates for this current time).
Will probably win but you need to consider how comfortable you are with the risk/reward.